Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,028 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development and validation of a machine learned algorithm to IDENTIFY functionally significant coronary artery disease.
Stuckey T, Meine F, McMinn T, Depta JP, Bennett B, McGarry T, Carroll W, Suh D, Steuter JA, Roberts M, Gillins HR, Lange E, Fathieh F, Burton T, Khosousi A, Shadforth I, Sanders WE Jr, Rabbat MG. Stuckey T, et al. Among authors: carroll w. Front Cardiovasc Med. 2022 Sep 2;9:956147. doi: 10.3389/fcvm.2022.956147. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36119746 Free PMC article.
Identifying novel phenotypes of elevated left ventricular end diastolic pressure using hierarchical clustering of features derived from electromechanical waveform data.
Burton T, Ramchandani S, Bhavnani SP, Khedraki R, Cohoon TJ, Stuckey TD, Steuter JA, Meine FJ, Bennett BA, Carroll WS, Lange E, Fathieh F, Khosousi A, Rabbat M, Sanders WE. Burton T, et al. Front Cardiovasc Med. 2022 Sep 23;9:980625. doi: 10.3389/fcvm.2022.980625. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36211581 Free PMC article.
Multicenter validation of a machine learning phase space electro-mechanical pulse wave analysis to predict elevated left ventricular end diastolic pressure at the point-of-care.
Bhavnani SP, Khedraki R, Cohoon TJ, Meine FJ 3rd, Stuckey TD, McMinn T, Depta JP, Bennett B, McGarry T, Carroll W, Suh D, Steuter JA, Roberts M, Gillins HR, Shadforth I, Lange E, Doomra A, Firouzi M, Fathieh F, Burton T, Khosousi A, Ramchandani S, Sanders WE Jr, Smart F. Bhavnani SP, et al. Among authors: carroll w. PLoS One. 2022 Nov 15;17(11):e0277300. doi: 10.1371/journal.pone.0277300. eCollection 2022. PLoS One. 2022. PMID: 36378672 Free PMC article.
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial.
Parker CC, Clarke NW, Cook AD, Kynaston H, Catton CN, Cross WR, Petersen PM, Persad RA, Saad F, Bower LC, Logue J, Payne H, Forcat S, Goldstein C, Murphy C, Anderson J, Barkati M, Bottomley DM, Branagan J, Choudhury A, Chung PWM, Cogley L, Goh CL, Hoskin P, Khoo V, Malone SC, Masters L, Morris SL, Nabid A, Ong AD, Raman R, Tarver KL, Tree AC, Worlding J, Wylie JP, Zarkar AM, Parulekar WR, Parmar MKB, Sydes MR; RADICALS investigators. Parker CC, et al. Lancet. 2024 May 16:S0140-6736(24)00548-8. doi: 10.1016/S0140-6736(24)00548-8. Online ahead of print. Lancet. 2024. PMID: 38763154 Free article.
Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial.
Parker CC, Kynaston H, Cook AD, Clarke NW, Catton CN, Cross WR, Petersen PM, Persad RA, Pugh CA, Saad F, Logue J, Payne H, Bower LC, Brawley C, Rauchenberger M, Barkati M, Bottomley DM, Brasso K, Chung HT, Chung PWM, Conroy R, Falconer A, Ford V, Goh CL, Heath CM, James ND, Kim-Sing C, Kodavatiganti R, Malone SC, Morris SL, Nabid A, Ong AD, Raman R, Rodda S, Wells P, Worlding J, Parulekar WR, Parmar MKB, Sydes MR; RADICALS investigators. Parker CC, et al. Lancet. 2024 May 16:S0140-6736(24)00549-X. doi: 10.1016/S0140-6736(24)00549-X. Online ahead of print. Lancet. 2024. PMID: 38763153 Free article.
ENSEMBLE PLUS: final results of shorter ocrelizumab infusion from a randomized controlled trial.
Hartung HP, Berger T, Bermel RA, Brochet B, Carroll WM, Holmøy T, Karabudak R, Killestein J, Nos C, Patti F, Perrin Ross A, Vanopdenbosch L, Vollmer T, Buffels R, Garas M, Kadner K, Manfrini M, Wang Q, Freedman MS. Hartung HP, et al. Among authors: carroll wm. J Neurol. 2024 Apr 22. doi: 10.1007/s00415-024-12326-z. Online ahead of print. J Neurol. 2024. PMID: 38649522
1,028 results